Medications
FDA-approved and compounded GLP-1s, prescribed online.
All 9 of our GLP-1 options, with pricing, indications, and what each is. Choose the brand-name product your clinician prescribes, or a compounded preparation when appropriate.
FDA-approved
Brand-name medications
FDA-approved Wegovy® and Zepbound® for chronic weight management, plus Ozempic® and Mounjaro® for type 2 diabetes. Dispensed by US-licensed pharmacies on a cash-pay basis.
Ozempic®
FDA-approved semaglutide from Novo Nordisk, prescribed online by a US-licensed clinician when clinically appropriate. Cash-pay; not billed to insurance.
From $1,299/mo
Wegovy®
Access FDA-approved Wegovy® (semaglutide) through a US-licensed clinician if it's right for you. Reviewed online, prescribed when clinically appropriate, shipped to your door.
From $1,349/mo
Mounjaro®
FDA-approved tirzepatide from Eli Lilly, prescribed online by a US-licensed clinician when clinically appropriate. Cash-pay; not billed to insurance.
From $1,349/mo
Zepbound®
Access FDA-approved Zepbound® (tirzepatide) — the dual GIP / GLP-1 receptor agonist from Eli Lilly — through a US-licensed clinician if it's right for you.
From $1,069/mo
Compounded · §503A
Compounded GLP-1s
Compounded semaglutide and tirzepatide prepared on a per-patient basis by US-licensed pharmacies when a licensed clinician determines a commercially available, FDA-approved product is not clinically appropriate.
Semaglutide injection
A weekly subcutaneous GLP-1 injection, prepared on a per-patient basis by a US-licensed compounding pharmacy when a licensed clinician determines it is the right fit for your care.
From $269/mo
Semaglutide oral
A daily oral GLP-1 tablet for patients who prefer not to inject, prepared on a per-patient basis by a US-licensed compounding pharmacy when a licensed clinician determines it is the right fit for your care.
From $299/mo
Tirzepatide injection
A weekly subcutaneous dual GIP / GLP-1 injection, prepared on a per-patient basis by a US-licensed compounding pharmacy when a licensed clinician determines it is the right fit for your care.
From $359/mo
Compounded · Microdose
Microdose compounded GLP-1s
Low-dose compounded preparations for patients prioritizing tolerability or maintenance dosing under clinician guidance.
Semaglutide microdose
A low-dose weekly semaglutide injection, prepared on a per-patient basis by a US-licensed compounding pharmacy for patients prioritizing tolerability or maintenance dosing under clinician guidance.
From $179/mo
Tirzepatide microdose
A low-dose weekly dual GIP / GLP-1 injection, prepared on a per-patient basis by a US-licensed compounding pharmacy for patients prioritizing tolerability or maintenance dosing under clinician guidance.
From $199/mo
Disclosures
FDA-approved Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. FDA-approved Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Pallas dispenses these brand-name products through US-licensed pharmacies on a cash-pay basis; insurance routing is not currently supported. Compounded medications are prepared by US-licensed compounding pharmacies on a per-patient basis when a licensed clinician determines they are clinically appropriate; 503A pharmacies are licensed and inspected by state boards of pharmacy. Compounded preparations themselves are not FDA-approved, are not generic versions of any brand-name drug, and have not been evaluated by the FDA for safety, efficacy, or quality. Treatment requires clinical eligibility and is at the discretion of the prescribing provider. The trademark owners listed above are not affiliated with, sponsors of, or endorsers of Pallas Health.